EGFR and colonic neoplasm: In in vivo colon cancer studies, conjugates of nanodiamonds with chemotherapeutic agents: ND-cisplatin and ND-cetuximab combined with monoclonal antibodies against the epidermal growth factor receptor (EGFR) showed selective binding of the conjugate to antibody-bearing cancer cells.